CorMedix (CRMD) Net Income towards Common Stockholders (2010 - 2025)

CorMedix has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting $14.0 million for Q4 2025.

• Net Income towards Common Stockholders for Q4 2025 came in at $14.0 million, down 56.9% year-over-year; the trailing twelve-month figure through Dec 2025 was $165.1 million (up 14429.32% YoY), and the FY2025 annual result was $163.1 million, up 14253.43% from the prior year.
• Net Income towards Common Stockholders came in at $14.0 million for Q4 2025 at CorMedix, down from $108.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $108.5 million in Q3 2025 to a low of -$14.5 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is $911594.0 (2021), against an average of $6.5 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 250.96% in 2023 and surged 4008.55% in 2025, its largest moves.
• CorMedix's Net Income towards Common Stockholders stood at -$9.7 million in 2021, then increased by 15.08% to -$8.2 million in 2022, then slumped by 74.94% to -$14.4 million in 2023, then surged by 326.52% to $32.5 million in 2024, then slumped by 56.9% to $14.0 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at $14.0 million (Q4 2025), $108.5 million (Q3 2025), and $21.9 million (Q2 2025), per Business Quant data.